

()

//
//

, ,

*

:

,

,

:

()

(/ ± /)

(/ ± /)

VAS

/ ± /

:

($P < /$)

/ ± /

/ ± /

($P < /$)

/ ± /

($P = /$)

($P = /$)

:

,

:

()

()

()

()

()

()

()

,

.()

()

()

.()

.()

()

 H_1

.()

/ $\pm$ /) :(H_1, H_2 (/ $\pm$ /

()

.()

/ ± /
(P < /) / ± /
.
VAS (visual Analysis scale)
(P= /)
VAS .()
 / ± /
(P< /) / ± / (-) (-)
(-)
 / ± / VAS
 / ± / -
(P < /) SPSS-13

VAS					
/ ± /	/ ± /	/ ± /	/ ± /	/ ± /	/ ± /
/ ± /	/ ± /	/ ± /	/ ± /	/ ± /	/ ± /
/	/	/	/	/	/
-					

/ ± /
()
P= /)
(P= /
() VAS / ± /

(P= /)

VAS

/ ± /



(P= /)

(P= /)

/ ± / VAS

(P= /)

(P= /)



()

() ()

/ ,

.() VAS

. VAS

.(-)

.()

()

.()

Smith

.()

.() H₁,H₂

Drake

.()

Greene

%

.()

REFERENCES

1. Dacre JC, Goldman M. Toxicology and pharmacology of the chemical warfare agent sulfur mustard. *Pharmacol Rev* 1996;48(2):289-326.

2. Eisenmenger W, Drasch G, Von Clarmann M, Kretschmer E, Roeder G. Clinical and morphological findings on mustard gas (bis [2-chloroethyl]sulphide) poisoning. *J Forensic Sci* 1991;36(6):1688-98.
3. Fisher DA. Adverse effects of topical Corticosteroids use. *West J Med* 1995;162:123-6.
4. Berberin BJ. The addition of topical Doxepin to corticosteroid therapy. An improved treatment regimen for atopic dermatitis. *Int J Dermatol* 1999;38:145-8.
5. Schmack I, Kruse FE, Bauer A, Volcker HE, Dithmar S. Neurodermatitis: A risk factor for the development of squamous cell carcinoma. *Ophthalmologie* 2006;103:141-3.
6. Krajnik M, Zylicz Z. Pruritus in Advanced internal disease pathogenesis & treatment. *Neth J Med*. 2001;58:27-40.
7. Simons FER, Simons KJ. Drug therapy: The pharmacology and use of H1-receptor antagonists drugs. *N Engl J Med* 1994;330:1663-70.
8. Rihoux JP, Donnelly F, Burtin B. The clinical efficacy of H1 antagonists in urticaria and rhinitis. *J Allergy Clin Immunol* 1998;102(2):33-4.
9. Archer CB. Mediators of heat urticaria. *Clin Exp Dermatol* 1988; 13:418.
10. Rice P. Sulphur mustard injuries of the skin. Pathophysiology and management. *Toxicol Rev* 2003;22:111-8.
11. Herman SM, Vender RB. Antihistamines in the treatment of Atopic Dermatitis. *J Cutan Med Surg* 2003;7(6):467-73.
12. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. *Ann Pharmacother* 1997;31(5):633-5.
13. Drake LA, Millikan LE. The antipruritic effect of 5% Doxepin cream in patients with eczematous dermatitis, Doxepin Study Group. *Arch Dermatol* 1995;131(12):1403-8.
14. Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing Doxepin with diphenhydramine for the treatment of chronic urticaria. *J Am Acad Dermatol* 1985;12(4):669-75.
15. Simons FE. Advances in H₁-Antihistamines. *N Engl J Med* 2004; 351: 2203-17.
16. Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria clinical efficacy of cetirizine in comparison with Hydroxyzine and placebo. *J Allergy Clin Immunol* 1990;86:1014-8.
17. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of Fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized multicentre, double-blind, placebo-controlled, parallel-group study. *Br J Dermatol* 2003;148:1212-21.
18. Klein PA, Clark RAF. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. *Arch Dermatol* 1999; 135:1522-5.
19. Nordness M, Zacharisen MC. High Dose Cetirizine: A Case Report. *Cutis*, 2003; 71:396.

20. Bagenstose SE, Levin L, Bernstein JA. The addition of Zafirlukast to Cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. *J Allergy Clin Immunol* 2004;113:134-40.
21. Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist Cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists Hydroxyzine and Cetirizine in patients with chronic urticaria; *J Allergy Clin Immunol*; 1995; 95:685-93.
22. Diepgen TL; Early Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months; *Pediatr Allergy Immunol*; 2002; 13:278-86.